Demant recalls cochlear implants – will cost up to EUR 13.4m in 2021, with more consequences for 2022

Oticon Medical, the surgical division of hearing aid group Demant, has located a performance issue in a number of non-implanted Neuro Zti cochlear implants, and the company sees no other option than to immediately withdraw the product from the market.
Photo: Demant / PR
Photo: Demant / PR

Bad things often happen in threes, and they just keep coming for hearing aid manufacturer Demant. First, the company was hit by a cyber attack which effectively shut down the company for weeks, then the pandemic hit, and now Oticon Medical, the sugical division at Demant, is experiencing headwind.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading